Caricamento...
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
Over the past ten years, sorafenib, a multikinase inhibitor, has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Whereas only recently lenvatinib was shown to be noninferior to sorafenib, in terms of survival, all other age...
Salvato in:
| Pubblicato in: | Drugs Context |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioExcel Publishing Ltd
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6038776/ https://ncbi.nlm.nih.gov/pubmed/30002715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212533 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|